Evidence map›Paper›PMID 31708659›Full record

GuidelineCurrent oncology (Toronto, Ont.)2019

Clinical practice guideline for image-guided multimode tumour ablation therapy in hepatic malignant tumours.

G Z Wang, X H He, Y Wang, L C Xu, H Z Huang, Y H Wang, Z Shen, X D Qu, X Y Ding, J J Yang and 1 more

Open access · goldAbstract readPractice Guideline
In one paragraph

Guideline in Current oncology (Toronto, Ont.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Article
  4. Article
  5. [Chinese expert consensus on the clinical management of liver disease-associated thrombocytopenia syndrome].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

G Z WangDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
X H HeDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
Y WangDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
L C XuDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
H Z HuangDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
Y H WangDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
Z ShenDepartment of Oncology, Affiliated Shanghai 6th People's Hospital, Shanghai Jiaotong University, Shanghai, P.R.C.
X D QuDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, P.R.C.
X Y DingDepartment of Interventional Radiology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, P.R.C.
J J YangDepartment of Interventional Radiology, Changhai Hospital, Naval Medical University, Shanghai, P.R.C.
W T LiDepartment of Interventional Oncology, Fudan University Shanghai Cancer Center, Shanghai, P.R.C.
Fudan University Shanghai Cancer Center · CNChanghai Hospital · CNFudan University · CNRuijin Hospital · CNShanghai Sixth People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multimode tumour ablation therapy is a treatment method that combines cryoablation with radiofrequency ablation, guided by medical imaging technology and based on precise planning, targeting, monitoring, and control of the thermal energy delivered, with the aim of achieving a whole-body antitumour immune response to malignant tumours. To develop standardized criteria for the application of multimode tumour ablation therapy to malignant hepatic tumours, to facilitate actualization of the criteria in various hospitals, and to ensure therapeutic efficacy and safety, the Society of Interventional Therapy of the Chinese Anti-Cancer Association and the Solid Tumor Theranostics Committee of the Shanghai Anti-Cancer Association assembled experts who specialize in oncology to discuss this treatment method and to arrive at a clinical practice consensus guideline for the indications, contraindications, and techniques of multimode tumour ablation therapy for malignant hepatic tumours.

Indexed as

Catheter AblationSurgery, Computer-AssistedConsensusHumansLiverLiver Neoplasmsconsensus statementscryoablationCryosurgeryliver neoplasmsradiofrequency ablation

Identifiers

PMID31708659
PMCPMC6821125
OpenAlexW2981720270

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.